-+ 0.00%
-+ 0.00%
-+ 0.00%

Ascendiant Capital Maintains Buy on NovaBay Pharmaceuticals, Adjusts Price Target To $0.85 (1-35 Reverse Stock Split)

Benzinga·11/11/2024 17:44:50
Listen to the news

Ascendiant Capital analyst Edward Woo maintains NovaBay Pharmaceuticals (AMEX:NBY) with a Buy, adjusts target to $0.85 from $8 (1-35 Reverse Stock Split).